Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmacokinetic studies,

Pharmacokinetic studies are designed to measure quantitatively the rate of uptake and metaboHsm of a material and determine the absorbed dose to determine the distribution of absorbed material and its metaboHtes among body fluids and tissues, and their rate of accumulation and efflux from the tissues and body fluids to determine the routes and relative rates of excretion of test material and metaboHtes and to determine the potential for binding to macromolecular and ceUular stmctures. [Pg.237]

Pharmacokinetic studies should allow an assessment of the relationship between the environmental-exposure conditions and the absorbed dose, and how these influence the doses of test material and metaboHtes received by various body tissues and fluids, and the potential for storage. Numerous texts are available on the design and conduct of metaboHsm and pharmacokinetic studies (117—119). [Pg.237]

Vinyhdene chloride is hepatotoxic, but does not appear to be a carcinogen (13—18). Pharmacokinetic studies indicate that the behavior of vinyl chloride and vinyhdene chloride in rats and mice is substantially different (19). No unusual health problems have been observed in workers exposed to vinyhdene chloride monomer over varying periods (20). Because vinyhdene chloride degrades rapidly in the atmosphere, air pollution is not likely to be a problem (21). Worker exposure is the main concern. Sampling techniques for monitoring worker exposure to vinyhdene chloride vapor are being developed (22). [Pg.428]

Bopindolol is a long-acting, nonselective P-adrenoceptor blocker. It has mild membrane stabilizing activity and ISA. In vivo, the compound is hydrolyzed to its active metabohte. Because of this prodmg feature the onset of action is slower than other available P-adrenoceptor blockers. Preliminary pharmacokinetic studies indicate that the compound is weU absorbed, is 70% bioavailable, and peak plasma levels are achieved in about 2 h. Whereas its elimination half-life is 4—8 h, P-adrenoceptor blocking action (- 40%) is stiU apparent after 48 h. The dmg is being studied in hypertension, angina, and arrhythmias (43). [Pg.119]

Muzolimine (710), a 1-substituted 2-pyrazolin-5-one derivative, is a highly active diuretic, differing from the structures of other diuretics since it contains neither a sulfonamide nor a carboxyl group. It has a saluretic effect similar to furosemide and acts in the proximal tubule and in the medullary portion of the ascending limb of the loop of Henle. Pharmacokinetic studies in dogs, healthy volunteers and in patients with renal insufficiency show that the compound is readily absorbed after oral administration (B-80MI40406). [Pg.296]

Vertex also put in clinical trial VX-765, another caspase-1 -specific, YVAD-derived peptidomimetic that is in vitro slightly more potent then pralnacasan (IC50 0.8 nM). Evaluation of VX-765 in a mouse model of oxazolone-induced dermatitis showed a dose-dependent (10-100 mg/kg) inhibition of ear inflammation. Consequently, VX-765 was enrolled in a 4-week phase Ila safety and pharmacokinetic study for psoriasis. However, Vertex has not communicated any results yet. [Pg.333]

In summary, the characteristics of the drug and the disease or condition may suggest a likely route and mode of delivery. Considerable vork is required to develop and optimise an appropriate drug presentation. The suitability of any particular strategy must be verified by undertaking the extensive pharmacodynamic and pharmacokinetic studies that form part of the pre-clinical and clinical trials. [Pg.55]

Note Derivatization with this reagent sequence in combination with extraction and TLC separation is speciftc for amitriptyline and nortriptyline in the analysis of plasma furthermore its high sensitivity allows its employment in pharmacokinetic studies, e. g. after the oral administration of a single dose of 25 mg amitriptyline. [Pg.58]

Toxicology studies must be performed in at least two animal species. If the toxicity profile of the compound is acceptable, then it joins the hit or lead list of compounds to proceed. The metabolism of the compound must be understood and pharmacokinetic studies must be performed in small and large animals. Efficacy studies must be performed in relevant animal models, especially in chimpanzees when more than one candidate is identified and a choice has to be made before proceeding to studies in humans. The ultimate preclinical steps include various studies testing drug combinations in vitro and in vivo, selection of resistant viruses, viral fitness, pyrophosphorolysis, and others. [Pg.28]

Pharmacokinetic studies demonstrated good oral bioavailability of maraviroc and a terminal half-life of 16-23 h following multiple dosing (Abel et al. 2003 Walker et al. 2005). Single doses of up to 900 mg and multiple doses of up to 300 mg BID for 28 days were well tolerated (Abel et al. 2003 Russell et al. 2003 Walker et al. 2005). In Phase 2a studies, treatment-naive HIV-1 patients with R5 virus who received maraviroc monotherapy at doses ranging from 25 mg QD to 300 mg BID for 10 days experienced a median viral load reduction of 1.64 log jg copies/mL and... [Pg.188]

Alcohol can affect the metabolism of trichloroethylene. This is noted in both toxicity and pharmacokinetic studies. In toxicity studies, simultaneous exposure to ethanol and trichloroethylene increased the concentration of trichloroethylene in the blood and breath of male volunteers (Stewart et al. 1974c). These people also showed "degreaser s flush"—a transient vasodilation of superficial skin vessels. In rats, depressant effects in the central nervous system are exacerbated by coadministration of ethanol and trichloroethylene (Utesch et al. 1981). [Pg.171]

Liu, A. et al.. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin, J. Pharm. Biomed. Anal, 40, 720, 2006. [Pg.85]

Chapter 9 shows the importance of PLC in the critical field of medical research, with representative examples of the applications to amino acids, carbohydrates, lipids, and pharmacokinetic studies. [Pg.9]

Pharmacokinetic studies of Ai-pyridinyl-indole-3-(alkyl)carboxamides and derivatives 95... [Pg.225]

H. Kanerva, Pharmacokinetic Studies on Deramciclane, Ph.D. dissertation. University of Kuopio, Kuopio, 1999. [Pg.839]

CYP3A4 and 2D6 are the major enzymes involved in the metabolism of galantamine. Pharmacokinetic studies with inhibitors of this system have resulted in increased galantamine concentrations or reductions in clearance. Similarly to donepezil, if inhibitors are given concurrently with galantamine, monitoring for increased cholinergic side effects should be done. Studies with inducers of these enzymes have not been completed.37... [Pg.520]

Lenalidomide was approved recently for the indication of myelodysplastic syndrome where the 5q deletion is present. Since lenalidomide is an analog of thalidomide, all the same precautions must be taken to prevent phocomelia. The time to maximum lenalidomide concentrations occurs 0.5 to 4 hours after the dose. The terminal half-life ranges from 3 to 9 hours. Approximately 65% of lenalidomide is eliminated unchanged in the urine, with clearance exceeding the glomerular filtration rate. To date, no pharmacokinetic studies have been done in patients with renal dysfunction. Lenalidomide is used in the treatment of myelodysplastic syndrome and multiple myeloma. Other side effects are neutropenia, thrombocytopenia, deep vein thrombosis, and pulmonary embolus. [Pg.1293]

Absorption, Distribution, Metabolism, and Excretion. There are no data available on the absorption, distribution, metabolism, or excretion of diisopropyl methylphosphonate in humans. Limited animal data suggest that diisopropyl methylphosphonate is absorbed following oral and dermal exposure. Fat tissues do not appear to concentrate diisopropyl methylphosphonate or its metabolites to any significant extent. Nearly complete metabolism of diisopropyl methylphosphonate can be inferred based on the identification and quantification of its urinary metabolites however, at high doses the metabolism of diisopropyl methylphosphonate appears to be saturated. Animal studies have indicated that the urine is the principal excretory route for removal of diisopropyl methylphosphonate after oral and dermal administration. Because in most of the animal toxicity studies administration of diisopropyl methylphosphonate is in food, a pharmacokinetic study with the compound in food would be especially useful. It could help determine if the metabolism of diisopropyl methylphosphonate becomes saturated when given in the diet and if the levels of saturation are similar to those that result in significant adverse effects. [Pg.108]

Table 4.1 Some pharmacokinetic studies of antidepressants in different ethnic groups... Table 4.1 Some pharmacokinetic studies of antidepressants in different ethnic groups...
Midha, K. K. et al. (1988b). A pharmacokinetic study oftrifluoperazine in two ethnic populations. Psychopharmacology, 95, 333-8. [Pg.58]


See other pages where Pharmacokinetic studies, is mentioned: [Pg.537]    [Pg.38]    [Pg.322]    [Pg.30]    [Pg.299]    [Pg.328]    [Pg.179]    [Pg.646]    [Pg.59]    [Pg.106]    [Pg.60]    [Pg.43]    [Pg.167]    [Pg.263]    [Pg.96]    [Pg.795]    [Pg.94]    [Pg.222]    [Pg.223]    [Pg.224]    [Pg.757]    [Pg.193]    [Pg.299]    [Pg.673]    [Pg.96]    [Pg.195]   
See also in sourсe #XX -- [ Pg.59 ]

See also in sourсe #XX -- [ Pg.173 ]

See also in sourсe #XX -- [ Pg.30 , Pg.500 ]

See also in sourсe #XX -- [ Pg.500 ]




SEARCH



Pharmacokinetics Pharmacokinetic studies

© 2024 chempedia.info